On September 22, 2015 NewLink Genetics Corporation (NASDAQ:NLNK), a biopharmaceutical company at the forefront of developing and commercializing novel immuno-oncology product candidates to improve the lives of patients with cancer, reported that the company will participate in PurpleStride Iowa, a Pancreatic Cancer Action Network (PanCAN) event to promote awareness and raise funds for the fight against pancreatic cancer, the nation’s fourth leading cause of cancer death (Press release, NewLink Genetics, SEP 22, 2015, View Source [SID:1234507512]). The PurpleStride Iowa PanCAN walk is on Saturday, Sept. 26 at 9:30 a.m. at Raccoon River Park.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
PurpleStride Iowa is the fourth PurpleStride walk the NewLink Genetics team (a Gold Sponsor for all 2015 PurpleStride walks) will participate in following successful fundraising efforts in Boston, Austin and Los Angeles. PanCAN raises funds to advance research, support patients and create hope for the pancreatic cancer community. Money raised during the PurpleStride walks will go to personalized support for patients, research grants and advocacy efforts to increase federal funding for pancreatic cancer research.
Pancreatic cancer is expected to become the second-leading cause of cancer-related deaths in the U.S. by 2020. It is one of the deadliest cancers, with a five-year survival rate of just seven percent. In 2015, an estimated 49,000 Americans will be diagnosed with pancreatic cancer and approximately 40,500 will die from the disease.
"Over the past 40 years, there has been little progress made towards increasing the survival rate for people with pancreatic cancer," said Charles Link, Chief Executive Officer and President of NewLink Genetics. "I am proud to count so many NewLink employees from all of our offices participating in the PurpleStride walks and working (both in and out of the office) to help find a new treatment for this devastating disease."
To join the NewLink Genetics team, or make a donation, please visit the NewLink Genetics team page. To learn more about the Pancreatic Cancer Action Network and how you can make a difference, visit www.pancan.org.